VEGF、COX-2、MMP-9在乳腺癌组织中的表达对乳腺钼靶x线征象的影响

目的探讨乳腺癌组织中血管内皮细胞生长因子（VEGF）、环氧化酶-2（COX-2）、基质金属蛋白酶-9（MMP-9）的表达对乳腺钼靶x线征象的影响,并初步探讨乳腺钼靶x线征象与分子病理学之间的关系。方法收集经乳腺钼靶X线检查、手术和病理证实的乳腺癌患者69例,将乳腺钼靶x线征象分为毛刺征、钙化征、异常血管征、淋巴结转移征,分析VEGF、COX-2、MMP-9表达对以上征象的影响。结果乳腺钼靶x线征象有毛刺征组VEGF、COX-2、MMP-9阳性表达率明显高于无毛刺征组（P〈0．05）;钙化组与无钙化组VEGF、COX-2、MMP-9阳性表达率差异无统计学意义（P〉0．05）;有异常血管征组VEGF、COX-2、MMP-9阳性表达率明显高于无异常血管征组（P〈0．05）;有淋巴结转移征组VEGF、COX-2、MMP-9阳性表达率明显高于无淋巴结转移征组（P〈0．05）。结论VEGF、COX-2、MMP-9高表达对乳腺钼钯x线征象毛刺征、异常血管征、淋巴结转移征的出现存在影响,并可作为乳腺钼钯X线恶性征象的生物学基础。     

人脑膜瘤血管内皮生长因子表达及生物学意义

[目的]研究血管内皮生长因子(VEGF)在人脑膜瘤中的表达及其生物学意义.[方法]采用免疫组织化学方法检测51例脑膜瘤(WHO分级良性38例,非典型11例,恶性2例)VEGF蛋白的表达水平和微血管密度(MVD).[结果]良性脑膜瘤VEGF阳性表达率86.8%(33/38),不典型、恶性脑膜瘤VEGF阳性表达率为84.6%(11/13)(P＞0.05).而3例正常脑膜组织未见VEGF表达(P＜0.05).良性、非典型及恶性脑膜瘤的MVD分别为131.08±115.93和145.12±99.21(P＞O.05),VEGF表达阴性的脑膜瘤其MVD为88.25±59.86,VEGF表达呈 、 、 的MVD为102.25±149.55,108.12±54.43,172.36±118.58,两者表达成正相关(r=O.45,P＜0.05).VEGF表达与脑膜瘤的侵袭性、脑浸润性无关.[结论]VEGF在脑膜瘤的血管形成中起重要作用,可能参与脑膜瘤的形成,但与脑膜瘤的良性向非典型转变、脑浸润性、侵袭性等生物学特性无关.     

缺氧诱导因子-1α、VEGF在进展期胃癌中的表达及意义

目的揭示进展期胃癌中缺氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)的表达规律,分析其与胃癌临床病理特征的关系,以探讨HIF-1α蛋白在胃癌血管形成中的作用.方法应用免疫组化方法检测50例胃癌组织HIF-1α、VEGF蛋白及微血管密度(MVD)的表达.结果胃癌组织HIF-1α蛋白与VEGF阳性表达率分别为68%(34/50)和62%(31/50),MVD平均计数为23.14±11.58;HIF-1α表达与淋巴结转移有关(P＜0.05);VEGF、MVD表达与肿瘤浸润深度(P＜0.05)、淋巴结转移(P＜0.05)和PTNM临床分期(P＜0.05)密切相关;HIF-1α与VEGF表达密切相关(x2=4.96,P＜0.05);HI-1α或VEGF表达阳性的MVD值显著高于阴性组(P＜0.05).结论HIF-1α、VEGF是反映胃癌浸润转移等生物学行为的重要指标,HIF-1α诱导VEGF表达从而促进肿瘤血管生成可能参与胃癌的进展.     

化疗前后宫颈癌中VEGF表达和微血管密度变化的研究

目的:观察宫颈癌化疗前后癌组织中微血管形成及VEGF表达的变化,分析二者与临床病理因素和化疗疗效之间的关系.方法:免疫组织化学S-P法检测54例宫颈癌经单一拓扑替康化疗前后癌组织中的微血管密度(MVD)及癌细胞VEGF的表达水平.结果:化疗前MVD和VEGF的表达与病理类型有关,腺癌明显高于鳞癌,差异有显著性(P＜0.05);VEGF阳性组MVD值比VEGF阴性组高,差异有显著性(P＜0.001),且VEGF与MVD值呈正相关关系(P＜0.05);化疗前、后MVD值分别为76.22±31.25,52.22±32.56,差异有显著性(P＜0.005);化疗前、后VEGF的阳性表达率分别为28(51.9%)、12(22.2%),差异有显著性(P＜0.001);化疗疗效Ⅱ级(有效)和Ⅲ级(显效)的MVD和VEGF表达均高于无效组,差异有显著性(P＜0.05).结论:VEGF能促进宫颈癌新生血管形成.拓扑替康化疗可降低肿瘤细胞VEGF阳性表达率,对抑制肿瘤血管生长有一定的作用.肿瘤中VEGF促进肿瘤微血管生长的同时也有利于化疗药物发挥药效.     

卵巢癌组织中VEGF及MVD表达及其临床意义

目的 分析微血管密度(MVD)以及卵巢上皮性肿瘤血管内皮生长因子(VEGF)的表达与卵巢癌临床病理因素的关系及两者的相关性.方法 选取手术切除的卵巢上皮性肿瘤标本88例以及正常卵巢组织标本35例,采用免疫组化染色方法检测所有标本中VEGF及MVD的表达情况,分析两者相关性及与卵巢上皮性肿瘤临床病理因素的关系.结果 VEGF在卵巢癌组织中的表达阳性率为92.0％及MVD平均值为(30.26±8.69),显著高于良性卵巢上皮性肿瘤组织VEGF的阳性表达率[52.6％,(11.52±3.46)] (P ＜0.05);而良性卵巢上皮性肿瘤组织中VEGF阳性表达率及MVD平均值均高于正常对照组(P＜0.05).VEGF阳性表逸的卵巢癌组织中MVD平均值显著高于VEGF阴性表达者,VEGF阳性表达与MVD平均值呈正相关(P＜0.05).卵巢癌组织中VEGF阳性表达与肿瘤临床分期及细胞分化程度存在明显相关性(P＜0.05),而与肿瘤直径、组织学类型以及患者年龄无明显相关性(P＞0.05).MVD与肿瘤临床病理特征无明显相关性(P＞0.05).结论 VEGF及MVD均能反映卵巢上皮性肿瘤的良恶性和恶性进展程度,并可能成为卵巢癌临床生物学治疗的参考指标.     

食管鳞状细胞癌ID-2的表达及其与新生血管生成的关系

[目的]通过观察ID-2在食管鳞癌(ESCC)中的表达及其与微血管密度(MVD)的关系,探讨ID-2在ESCC发生及血管生成中的作用.[方法]应用SP法对115例ESCC组织、60例切缘正常组织进行ID-2免疫组化染色,检测癌组织、正常食管黏膜组织中ID-2的表达,并分析ID-2的表达与ESCC临床病理特征及与MVD之间的关系.[结果]ID-2在ES-CC组织中的阳性表达率为85.2％(98/115),切缘正常组织中阳性率15.0％ (9/60),两者差异有统计学意义(P＜0.01),其表达与患者年龄、性别及是否伴淋巴结转移均无关(P＞0.05),而与肿瘤浸润深度、MVD、肿瘤分期以及肿瘤分化程度有关(P＜0.05).ID-2高表达组术后生存率低(P＜0.05).[结论] ID-2在ESCC的发生及血管生成中起重要作用,可能是ESCC的重要促血管生成因子之一,ID-2蛋白高表达者ESCC患者预后差.     

CD105和VEGF、TGF-β1在结直肠癌的表达及其与浸润、转移和血管生成的关系

目的 探讨结直肠癌中CD105和VEGF、TGF-β1的表达及与血管生成的关系.方法 应用免疫组化方法检测60例结直肠癌中CD105标记的微血管密度(MVD)和VEGF、TGF-β1的表达.结果 60例结直肠癌中CD105表达的MVD为36.50±9.43.VEGF、TGF-β1表达的阳性率为68.3%,75.0%.MVD和VEGF、TGF-β1表达与肿瘤浸润深度、淋巴结转移和Dukes分期密切相关(P＜0.05).VEGF、TGF-β1表达均与MVD呈正相关(P＜0.01),TGF-β1与VEGF也呈正相关(P＜0.05).结论 CD105、VEGF、TGF-β1关系密切,三者联合检测可作为结直肠癌新生血管和浸润转移的有价值的标志物.     

PD-ECGF、VEGF及MVD在大肠癌及癌前病变中的表达

[目的]探讨血小板衍生内皮细胞生长因子(PD-ECGF)、血管内皮细胞生长因子(VEGF)及微血管密度(MVD)在大肠癌及癌前病变中的表达意义.[方法]采用免疫组织化学法,对43例大肠腺癌、71例癌前病变(包括47例腺瘤、24例增生性息肉)和20例正常肠黏膜(对照组)进行PD-ECGF、VEGF的染色,同时计数MVD.[结果]PDECGF在大肠腺癌、腺瘤、增生性息肉及对照组中阳性率分别为88.4％、61.7％、62.5％、30.0％,VEGF阳性率分别为95.3％、51.1％、33.3％、25.0％.腺癌组PD-ECGF及VEGF阳性率显著性高于腺瘤、增生性息肉及对照组(P＜0.05).腺瘤和增生性息肉中PD-ECGF阳性率显著高于对照组(P＜0.05).腺癌、腺瘤、增生性息肉及对照组中MVD计数分别为81.98±35.34、50.13±18.08、52.67±18.11、46.75±14.92 (F=11.656,P=0.003),且腺癌组MVD计数高于其他3组(P＜0.05).PD-ECGF、VEGF表达与MVD计数均呈正相关(r=0.389,P＜0.05;r=-0.398,P＜0.05).[结论]PD-ECGF及VEGF在腺癌组表达明显高于癌前病变及正常对照组,癌前病变组的表达高于对照组,并与MVD增多相一致.     

缺氧诱导因子1α在食管鳞癌组织中的表达及其与VEGF、MVD的关系

目的 探讨食管鳞癌组织中缺氧诱导因子1α(HIF-1α)、VEGF的表达及其与微血管密度(MVD)、肿瘤临床病理特征之间的关系.方法 采用免疫组化方法检测56例食管鳞癌及20例癌旁正常黏膜中HIF-1α、VEGF的表达,用Endoglin(CD105)单克隆抗体标记血管内皮细胞并计数MVD,分析其间的相关性及其与肿瘤临床病理特征之间的相关性.结果 食管鳞癌组织中HIF-1α和VEGF的阳性表达率显著高于正常组织(P＜0.01);HIF-1α和VEGF的表达均与淋巴结转移和TNM分期呈正相关(P＜0.05);VEGF的表达还与肿瘤浸润深度正相关(P＜0.05);HIF-1α的表达与VEGF的表达和MVD值呈正相关(P＜0.01).结论 HIF-1α及其靶基因VEGF在食管癌组织中明显上调,与肿瘤新生血管密切相关,HIF-1α可能通过诱导VEGF的表达参与食管鳞癌的血管生成,在食管癌的发生、发展及浸润过程中起了重要作用;联合检测HIF-1α和VEGF可能成为判断食管鳞癌生物学行为及预后的重要指标.     

乳腺癌VEGF的表达和微血管形成的关系及意义

目的 :探讨血管内皮生长因子 (VEGF)与肿瘤内微血管形成的关系 ,以及微血管密度 (MVD)与乳腺癌淋巴结转移和预后的关系。方法 :采用免疫组化 S- P法对 4 0例人乳腺浸润性导管癌组织中的 VEGF和 MVD进行检测。结果 :VEGF阳性者 MVD值显著高于阴性者 ,VEGF表达和MVD与乳腺癌淋巴结转移关系密切。结论 :VEGF与乳腺癌血管生成密切相关 ,VEGF和 MVD表达的增高对乳腺癌淋巴结转移有促进作用 ,MVD和 VEGF均可作为反映乳腺癌生物学行为的指标之一     

膀胱移行细胞癌的CT表现与Ki-67、VEGF和MVD表达的相关性

[目的]探讨膀胱移行细胞癌（BTCC）的CT表现与Ki-67、血管内皮生长因子（VEGF）和微血管密度（MVD）表达的关系。[方法]对41例经手术病理证实的BTCC，采用LDP免疫组化法，检测肿瘤标本中Ki-67、VEGF和MVD的表达，并分析其与术前CT征象的关系。[结果]Ki-67LI与VEGF、Ki-67LI与MVD、VEGF与MVD呈显著性正相关（r值分别为0．548、0．603、0．705，P均〈0．001）。Ki-67LI、VEGF和MVD表达与肿瘤呈分叶状、肿瘤多发、膀胱壁增厚、浆膜受侵、邻近器官受累等CT征象均有关（P〈0．05）。[结论]BTCC的CT征象与Ki-67LI、VEGF和MVD表达密切相关，当肿瘤有分叶征、肿瘤多发、相邻膀胱壁增厚、浆膜层受侵、邻近器官受累等CT征象时，提示肿瘤可能有较高的恶性程度、浸润能力及较差的预后。     

Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density,and contrast-enhanced ultrasound (CEUS)

To evaluate thyroid cancer in Chinese females with breast cancer by VEGF, MVD, and contrast-enhanced ultrasound (CEUS), 34 of 2,278 female inpatients with breast diseases who underwent routine thyroid ultrasonography were pathologically proved as thyroid cancer and enrolled into two groups: a breast cancer group and a non-breast cancer group. CEUS was performed and enhancement patterns were classified. Time-intensity curve parameters were analyzed to correlate with MVD CD34 and VEGF expression. Fourteen (2.6 %) and 20 (1.1 %) patients in breast cancer and non-breast cancer group were pathologically diagnosed as thyroid cancer. Six (42.8 %) and 0(0 %) patients showed high enhancement CEUS patterns of thyroid cancer in these two groups, respectively. The arrival time of time-intense curve was shorter, and the mean and peak intensity were higher in thyroid cancer in breast cancer group. The mean MVD counts and VEGF expression were significantly higher in thyroid and breast carcinomas in breast cancer group (P?<?0.01). We also found that the mean and peak intensity were significantly associated with MVD counts and VEGF expression (P?<?0.01). CEUS is recommended in evaluating the microcirculation of thyroid cancer in women with breast cancer and has the significant relationship with MVD counts and VEGF expression.     

Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer

This study was designed to elucidate the possible relationship between tumour related genes and angiogenesis in colon cancer. The protein expression of p53, bcl-2, Von Willebrand factor and vascular endothelial growth factor (VEGF) were analysed by immunohistochemistry in 57 paraffin-embedded colon cancer. The results showed that microvessel density (MVD) was lower in VEGF negative tumours than in VEGF positive ones (P<0.0001). MVD and VEGF in p53 negative tumours were significantly lower than in p53 positive tumours (respectively, P=0.003 and P<0.0001). Moreover, positive correlations were recorded between VEGF expression and MVD, and bcl-2 expression (respectively, P<0.0001 and P=0.009). Our data confirm the central role of VEGF in angiogenesis and suggest direct correlations among p53, bcl-2 and VEGF expression in colon cancer.     

Expression and clinical significance of vascular endothelial growth factor in benign and malignant tissues of breast

Objective:To detect the expression of vascular endothelial growth factor(VEGF)and microvessel density(MVD)count in breast benign affection,breast atypical hyperplasia and breast carcinoma in situ,and to clarify the relationship between VEGF expression,MVD and the clinicopathological features of these diseases. Methods:The expression of VEGF and MVD count in 115 cases breast benign diseases(including 40 breast fibroid tumor,40 breast cystic hyperplasia and 35 intraductal papilloma,19 breast atypical hyperplasias and 32 breast carcinomas in situ were examined by immunohistochemistry staining(SP-method). Results:The positive rate of VEGF in breast benign diseases,breast atypical hyperplasia and breast carcinoma in situ were 21.74%(25/115)、31.58.%(6/19)and 53.13%(17/32)respectively.It was the lowest in breast benign affection group,and was the highest breast carcinoma in situ group.The expression of VEGF increased gradually in the three groups(P＜0.05).The MVD count of the three groups were 14.41±2.59,18.89±4.47 and 21.13±4.12 respectively,It was the lowest in breast benign affection group,and was the highest breast carcinoma in situ group.The MVD count of the three groups increased gradually(P＜0.05).In VEGF positive group,MVD count was 19.41±4.78;In VEGF negative group,MVD count was 14.91±3.15.The MVD count was higher in VEGF positive group than that in VEGF negative group(P＜0.05). Conclusion:The results of this study suggested that VEGF could promote microvessel growth in breast tumors.The occurrence and progression of breast cancer might be related with the expression of VEGF.     

UP－REGULATION OF CYCLOOXYGENASE－2 GENE EXPRESSION CORRELATES WITH TUMOR ANGIOGENESIS IN HUMAN BREAST CANCER

Prostaglandins(PGs) play a critical role in tumor development and growth by regulating numerous biologic processes, including tumor angiogenesis[1]. Cyclooxygenase-2 (COX-2) is an inducible enzyme that converts arachidonic acid to PGs. Overexpression of the COX-2 gene in mammary glands of transgenic mice was sufficient to induce tumorigenesis[2]. COX-2expression may contribute to the synthesis of PGs, which have been related to carcinogenesis and tumor progression. Recent studies have sh…     

血管内皮生长因子在乳腺癌中的表达及与微血管生成的关系

目的 :探讨血管内皮生长因子 (VEGF)在乳腺癌中的表达及其与血管生成和病理参数的关系。方法 :采用S P免疫组织化学染色法检测 5 6例乳腺癌及 10例癌旁正常组织的VEGF表达 ,并对血管进行Ⅷ因子相关抗原的免疫组织化学染色 ,记数微血管密度。对 10例乳腺癌进行VEGFmRNA原位杂交检测。结果 :乳腺癌组织VEGF表达阳性率高于其癌旁正常组织 ,差异有显著意义 ,P <0 0 5。VEGF的表达与乳腺癌的病理分级密切相关 ,P <0 0 1。有淋巴结转移的VEGF表达率明显高于无淋巴结转移 ,P <0 0 5 ;而且随着VEGF表达的增强 ,乳腺癌组织内微血管密度明显增高 ,P <0 0 1。结论 :癌组织VEGF表达增强在肿瘤血管生成、生长及转移中起重要作用。     

VEGF、MVD和LN与大肠癌微转移的关系

 目的
探讨血管内皮生长因子(VEGF）、微血管密度(MVD）和层黏连蛋白(Laminin,LN）在大肠正常黏膜组织、大肠腺瘤
组织及大肠癌组织中的表达及临床意义。方法应用免疫组织化学SP法检测18例正常大肠黏膜组织、26例大肠腺瘤组
织和68例大肠癌组织中VEGF和LN的表达水平及MVD计数,并分析他们与大肠癌微转移的关系。结果从大肠正常黏膜
逐步发展为大肠癌的过程中,VEGF的表达水平、MVD计数及基底膜明显缺损率均逐渐增加,LN表达减少,大肠癌组
织中VEGF的阳性表达率和MVD计数与大肠癌的浸润深度、淋巴结转移、Dukes分期有关(P<0.05）。大肠癌组织中基
底膜缺损程度与淋巴结转移、Dukes分期有关(P<0.05）。结论 肿瘤的血管形成和LN的表达与大肠癌的淋巴结转移
、Dukes分期等临床病理特征密切相关,联合检测VEGF、MVD和LN的表达对判断大肠癌的浸润和转移倾向,进而估计
患者的恶性程度。     

VEGF-A和VEGF-C在乳腺癌组织中的表达及其意义

背景与目的:VEGF家族都与血管生成相关,血管内皮生长因子-A(vascularendothelialgrowthfactorA,VEGF-A)和血管内皮生长因子-C(vascularendothelialgrowthfactorC,VEGF-C)与肿瘤的生长和转移关系密切。本研究探讨乳腺癌组织中VEGF-A、VEGF-C的表达与癌细胞增殖、微血管密度(microvesseldensity,MVD)和淋巴结转移的关系。方法:采用免疫组织化学方法观察98例乳腺癌组织中VEGF-A、VEGF-C、增殖细胞核抗原(proliferatingcellnuclearantigen,PCNA)、CD34的表达情况。结果:98例乳腺癌组织中,VEGF-A阳性率为85.7%(84/98),VEGF-C阳性率90.8%(89/98),两者在淋巴结转移组表达均高于未转移组,差异具有显著性(P<0.05)。PCNA的表达随着VEGF-A、VEGF-C表达强度增强,肿瘤细胞增殖活性也随之增强(r=0.432,P=0.000;r=0.294,P=0.001)。淋巴结转移组MVD值(64.26±26.40)明显高于未转移组(50.29±29.35)(P<0.05),且随着VEGF-A表达增强,MVD也随之增高(r=0.327,P<0.001),VEGF-C表达与MVD无相关性(r=0.123,P>0.05)。结论:VEGF-A主要介导了血管生成、细胞增殖和转移;VEGF-C促进乳腺癌细胞增殖,与血管密度无关,与淋巴结转移密切相关。     

Breast Lesions： Correlation of Dynamic Contrast Enhancement Patterns on MR images with Tumor Angiogenesis

Objective To determine whether dynamic contrast -enhanced MRI features of the early -phase enhancement rate, enhancement amplitude, and signal-intensity (SI) time course are associated with the microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression of malignant and benign breast lesions. Methods Sixty patients with breast lesions, detected with physical examination or conventional mammography, were examined pre —operatively with dynamic contrast-enhanced MRI from December 1998 to June 2000. Of these 60 patients, histopathological correlation was available in 38. These 38 patients(aged 29–73 years) formed the basis of this study. SI changes during dynamic scanning were assessed quantitatively. Early-phase enhancement rate and enhancement amplitude were calculated. Time-SI curves of the lesions were obtained and classified according to their shapes as type I (which was steady enhancement to the end of the dynamic data acquisition at 7.5min.), type II (plateau of SI after avid initial contrast enhancement), or type III (washout of SI after avid initial contrast enhancement). The mean MVD and VEGF expression of the lesions were measured with immunohistochemical staining methods in all the pathologic specimens by a pathologist without knowledge of the results of the MR examination. Care was taken to ensure identical location in the plane of the MR image and pathologic specimens. The relationships among dynamic contrast-enhanced MRI features, MVD, and VEGF expression of benign and malignant breast lesions were analyzed. Results Histology revealed 21 malignancies and 17 benign lesions. The mean MVD and VEGF expression for the 21 malignant lesions were significantly higher than the mean MVD and VEGF expression for the 17 benign lesions (P<0.01). High VEGF expression of benign and malignant breast lesions showed a significant association with increased MVD (P< 0.01 ). Among all 38 lesions, greater (>60%) MR early-phase enhancement rate and time-SI curve type II or III showed a significant association with MVD and VEGF expression. All the differences mentioned above showed statistical significance (P<0.01) except the difference between VEGF expression and the distribution of curve types which had no statistical significance (P=0.069). No significant relationships were observed between the enhancement amplitude and MVD (P>0.05) and VEGF expression (P> 0.05). Regarding the distribution of MVD, the study showed that the greater MVD was most frequently observed at the marginal region of the breast cancers, although the distribution of MVD was heterogeneous in each lesion. Conclusions MVD and VEGF affect the contrast medium enhancement of breast lesions. The early -phase enhancement rate and time — SI curve types of benign and malignant breast lesions are closely related to MVD and VEGF. As a noninvasive method, contrast-enhanced MRI has a potential role in estimating the degree of angiogenesis of breast neoplasms.     

非小细胞肺癌中VEGF、MVD及PCNA的表达

目的 :探讨VEGF、MVD和PCNA在非小细胞肺癌 (NSCLC)中的表达及其生物学行为的关系。方法 :采用免疫组织化学方法 ,对病理确诊的 5 9例非小细胞肺癌组织进行VEGF、MVD和PCNA表达的检测。结果 :5 9例非小细胞肺癌的VEGF阳性表达率 6 4 4 % (38/5 9) ,其表达与NSCLC的组织分化程度、生存期有相关性 (P <0 0 5 ) ,与组织学类型、有无淋巴结转移、临床病理分期无关。PCNA阳性表达率 6 1 0 % (36 /5 9) ,表达与肿瘤组织类型、TNM分期、有无淋巴结转移无关 ,与组织分化程度及生存期有关 (P <0 0 5 )。 5 9例NSCLC的MVD值为 3～ 2 0 (M =9) ,与生存期有关 (P <0 0 5 )。结论 :VEGF、MVD和PC NA可以作为评价非小细胞肺癌预后的重要指标。